Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459 | 0.95 | AGTR1 (0.52) | AGTR1AGTR2 | |
| SCHEMBL317 | 0.94 | AGTR1 (0.55) | AGTR1AGTR2 | |
| SCHEMBL6536066 | 0.90 | AGTR1 (0.44) | AGTR1AGTR2 | |
| SCHEMBL7366694 | 0.89 | AGTR1 (0.56) | AGTR1AGTR2 | |
| SCHEMBL962 | 0.87 | AGTR1 (0.59) | AGTR1AGTR2 | |
| SCHEMBL186 | 0.87 | AGTR1 (0.65) | AGTR1AGTR2 | |
| SCHEMBL17031409 | 0.85 | AGTR1 (0.55) | AGTR1AGTR2 | |
| SCHEMBL7363748 | 0.85 | AGTR1 (0.61) | AGTR1AGTR2 | |
| SCHEMBL6545442 | 0.85 | AGTR1 (0.52) | AGTR1AGTR2 | |
| SCHEMBL10533864 | 0.84 | AGTR1 (0.49) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019048-B1 | USE OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREPARATION OF DRUGS TO INCREASE THE SURVIVAL RATE OF RENAL TRANSPLANT PATIENTS | MERCK SHARP DOHME ITALIA S P A (IT) | 2004-01-21 | — | — | EP | claimed |
| US-6576652-B2 | Administering substituted imidazoles, particular by losartan potassium, treatment of post-transplant hypertension. | MERCK SHARP & DOHME (ITALIA) S.P.A. (IT) | 2003-06-10 | — | — | US | claimed |
| US-20020115702-A1 | Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients | MERCK SHARP & DOHME (ITALIA) S.P.A. (IT) | 2002-08-22 | — | — | US | claimed |
| US-6300356-B1 | ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2001-10-09 | — | — | US | claimed |
| US-6201002-B1 | ADMINISTERING IMIDAZOLE DERIVATIVE TO TREAT CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS | MERCK & CO., INC. | 2001-03-13 | — | — | US | claimed |
| EP-1059843-A1 | METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 2000-12-20 | — | — | EP | claimed |
| US-5962500-A | HYPOSENSITVE AGENT | MERCK SHARP & DOHME CORP. | 1999-10-05 | — | — | US | claimed |
| WO-1999043210-A1 | METHOD FOR DECREASING QT DISPERSION OR INHIBITING THE PROGRESSION OF QT DISPERSION WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 1999-09-02 | — | — | WO | claimed |
| EP-0733366-B1 | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics | DU PONT (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0803252-A2 | Treatment of central nervous system disorders with imidazole angiotensin-II receptor antagonists | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-10-29 | — | — | EP | claimed |
| WO-1995026724-A1 | IMPROVEMENT OF INSULIN SENSITIVITY WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES | EIDE IVAR KONRAD (NO) | 1995-10-12 | — | — | WO | claimed |
| US-5210079-A | Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-11 | — | — | US | claimed |
| EP-0533840-A1 | TREATMENT OF CHRONIC RENAL FAILURE WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS. | DU PONT (US) | 1993-03-31 | — | — | EP | claimed |
| EP-0524946-A4 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS | — | 1993-03-24 | — | — | EP | claimed |
| EP-0524946-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-02-03 | — | — | EP | claimed |
| US-5153197-A | Treatment of hypertension with angiotensin II blocking imidazoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-06 | — | — | US | claimed |
| US-5140037-A | Administering cognition activators | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-18 | — | — | US | claimed |
| WO-1992000067-A2 | TREATMENT OF CHRONIC RENAL FAILURE WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-09 | — | — | WO | claimed |
| WO-1991014367-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS WITH IMIDAZOLE ANGIOTENSIN-II RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-10-03 | — | — | WO | claimed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115702-A1 | Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients | AGTR2, AGTR1, REN | AGTR1 2/4885AGTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.